ARCH Venture and Sofinnova Partners, two venture capital firms, led a $55m Series A funding round in Mozart Therapeutics, a biopharmaceutical company, with participation from Eli Lilly & Company, MRL Ventures Fund, Leaps by Bayer, Altitude Life Science Ventures and Alexandria Venture Investments. "Modulating the CD8 T reg network represents a novel way to tackle a root cause of immune system dysregulation. We are pleased to support the advancement of Mozart's innovative research that may hold promise to significantly impact the course of a wide range of diseases," Steve Gillis, ARCH Venture Partners Managing Director.